Global Venturing Review

The Big Ones EQRx formally launched a year ago with $200m from investors including GV and Nextech, and all its series A investors have now returned for a $500m series B round. The startup is collaborating with stakeholders including pharmaceutical companies to develop more affordable medicines, with late-stage cancer drugs a particular focus. It is … Continue reading "18 January 2021 – GV Returns for EQRx’s $500m Series B"